Inventiva S.A. (IVA.PA)
EUR 2.15
(2.38%)
EUR 2.15
(2.38%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 17.47 Million EUR | 43.5% |
| 2022 | 12.17 Million EUR | 190.39% |
| 2021 | 4.19 Million EUR | 1027.42% |
| 2020 | 372 Thousand EUR | -94.68% |
| 2019 | 6.99 Million EUR | 118.89% |
| 2018 | 3.19 Million EUR | -50.97% |
| 2017 | 6.52 Million EUR | -30.96% |
| 2016 | 9.44 Million EUR | 93.77% |
| 2015 | 4.87 Million EUR | 48.49% |
| 2014 | 3.28 Million EUR | 7.13% |
| 2013 | 3.06 Million EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 2.73 Million EUR | 0.0% |
| 2023 Q2 | 6.62 Million EUR | 0.0% |
| 2023 FY | 17.47 Million EUR | 43.5% |
| 2023 Q4 | 16.54 Million EUR | 0.0% |
| 2022 Q4 | 15.42 Million EUR | 0.0% |
| 2022 Q2 | 67 Thousand EUR | 0.0% |
| 2022 FY | 12.17 Million EUR | 190.39% |
| 2021 Q2 | 65 Thousand EUR | -12.16% |
| 2021 Q1 | 74 Thousand EUR | -64.93% |
| 2021 FY | 4.19 Million EUR | 1027.42% |
| 2021 Q4 | 4.05 Million EUR | 0.0% |
| 2020 FY | 372 Thousand EUR | -94.68% |
| 2020 Q1 | 87 Thousand EUR | -98.46% |
| 2020 Q2 | 74 Thousand EUR | -14.94% |
| 2020 Q4 | 211 Thousand EUR | 0.0% |
| 2019 FY | 6.99 Million EUR | 118.89% |
| 2019 Q4 | 5.66 Million EUR | 0.0% |
| 2019 Q2 | 1.33 Million EUR | -23.81% |
| 2019 Q1 | 1.74 Million EUR | -45.7% |
| 2018 Q4 | 3.22 Million EUR | 0.0% |
| 2018 FY | 3.19 Million EUR | -50.97% |
| 2018 Q2 | 4.15 Million EUR | 420.11% |
| 2018 Q1 | 799.25 Thousand EUR | -83.01% |
| 2017 FY | 6.52 Million EUR | -30.96% |
| 2017 Q1 | 1.63 Million EUR | -78.54% |
| 2017 Q2 | 5.24 Million EUR | 221.83% |
| 2017 Q4 | 4.7 Million EUR | 0.0% |
| 2016 Q4 | 7.59 Million EUR | 0.0% |
| 2016 Q2 | 6.73 Million EUR | 185.26% |
| 2016 Q1 | 2.36 Million EUR | -52.73% |
| 2016 FY | 9.44 Million EUR | 93.77% |
| 2015 FY | 4.87 Million EUR | 48.49% |
| 2015 Q4 | 4.99 Million EUR | 309.9% |
| 2015 Q3 | 1.21 Million EUR | -66.75% |
| 2015 Q2 | 3.66 Million EUR | 200.73% |
| 2015 Q1 | 1.21 Million EUR | 0.0% |
| 2014 FY | 3.28 Million EUR | 7.13% |
| 2014 Q2 | 820.73 Thousand EUR | 0.0% |
| 2014 Q1 | 820.73 Thousand EUR | 0.0% |
| 2014 Q3 | 820.73 Thousand EUR | 0.0% |
| 2014 Q4 | 1.21 Million EUR | 48.49% |
| 2013 Q3 | 766.12 Thousand EUR | 0.0% |
| 2013 Q1 | 766.12 Thousand EUR | 0.0% |
| 2013 Q4 | 820.73 Thousand EUR | 7.13% |
| 2013 FY | 3.06 Million EUR | 0.0% |
| 2013 Q2 | 766.12 Thousand EUR | 0.0% |
| 2012 Q4 | 766.12 Thousand EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | -276.659% |
| ABIVAX Société Anonyme | 4.62 Million EUR | -278.208% |
| Adocia SA | 2.15 Million EUR | -712.884% |
| Aelis Farma SA | 9.05 Million EUR | -93.031% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | -454.649% |
| genOway Société anonyme | 20.04 Million EUR | 12.817% |
| IntegraGen SA | 12.53 Million EUR | -39.399% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -5725.006% |
| Neovacs S.A. | 533.41 Thousand EUR | -3176.454% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -939.36% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -88185.512% |
| Sensorion SA | 4.74 Million EUR | -268.475% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -5797.797% |
| TME Pharma N.V. | 17 Thousand EUR | -102705.882% |
| Valbiotis SA | 4.73 Million EUR | -269.258% |
| TheraVet SA | 1.07 Million EUR | -1521.16% |
| Valerio Therapeutics Société anonyme | 1.8 Million EUR | -870.944% |
| argenx SE | 1.13 Billion EUR | 98.459% |
| BioSenic S.A. | 543 Thousand EUR | -3118.6% |
| Celyad Oncology SA | 102 Thousand EUR | -17034.314% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 92.71% |
| Genfit S.A. | 28.56 Million EUR | 38.817% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | -737.422% |
| Innate Pharma S.A. | 51.9 Million EUR | 66.326% |
| MaaT Pharma SA | 2.22 Million EUR | -684.425% |
| MedinCell S.A. | 9.16 Million EUR | -90.797% |
| Nanobiotix S.A. | 30.05 Million EUR | 41.856% |
| Onward Medical N.V. | 532 Thousand EUR | -3185.15% |
| Oryzon Genomics S.A. | 14.19 Million EUR | -23.15% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | -684.778% |
| Oxurion NV | 263 Thousand EUR | -6545.247% |
| Pharming Group N.V. | 245.31 Million EUR | 92.876% |
| Poxel S.A. | 1.98 Million EUR | -782.231% |
| GenSight Biologics S.A. | 1.26 Million EUR | -1279.4% |
| Transgene SA | 1.18 Million EUR | -1376.098% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.667% |
| Valneva SE | 153.71 Million EUR | 88.63% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 582.79% |